Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Phase 1 Completed 42 enrolled Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis

Timeline

Start: 2022-02-17
Primary completion: 2023-11-14
Completion: 2023-11-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Naftifine	Other / unclassified	2 %	Topical
Comparator	Naftifine	Other / unclassified	5 g	Topical
Subject	UHE-103	Unknown	4 g	Topical

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Summary

Timeline

Drugs

Indications